Quantcast

Latest Sipuleucel-T Stories

2011-06-29 19:04:00

SEATTLE, June 29, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S.

2011-06-23 15:30:00

NEW YORK, June 23, 2011 /PRNewswire/ -- For years, researchers have dreamed of curing prostate cancer with targeted drugs that could modulate the body's own immune system to attack and destroy malignant cancer cells.

2011-06-16 05:00:00

SEATTLE, June 16, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the NASDAQ OMX 26th Investor Program in London on June 21, 2011 at 9:30 a.m. GMT (4:30 a.m.

2011-06-13 17:32:00

SEATTLE, June 13, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., President and Chief Executive Officer received the Ernst & Young Entrepreneur Of The Year(®) 2011 Pacific Northwest Award in the Emerging Sciences category. Dr.

2011-06-03 12:24:15

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it.

2011-05-20 05:00:00

SEATTLE, May 20, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: ThinkEquity Annual Healthcare Conference in New York City, NY on May 25, 2011 at 1:00 p.m.

2011-05-19 07:15:00

AUBURNDALE, Mass., May 19, 2011 /PRNewswire/ -- Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S.

2011-05-18 17:00:00

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 2011 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

2011-05-18 17:00:00

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced three abstracts accepted for poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and the clinical trial of DN24-02 in bladder cancer at the upcoming American Society for Clinical Oncology annual meeting in Chicago, Illinois.

2011-05-16 13:50:00

MAYWOOD, N.J., May 16, 2011 /PRNewswire/ -- New Jersey Center for Prostate Cancer & Urology is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.


Word of the Day
postliminy
  • In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
  • In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.
The word 'postliminy' comes from a Latin word meaning 'threshold'.